Germany
· Delayed Price · Currency is EUR Pentixapharm Holding AG Company Description
Pentixapharm Holding AG operates as a clinical-stage radiopharmaceutical development company.
It focuses on developing CXCR4 ligand-based radiopharmaceutical approaches for diagnostic and therapeutic programs in various hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.
The company’s clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas; and PentixaFor, a Gallium-68-based companion diagnostic.
Its clinical studies for compounds have commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma.
In addition, the company’s PentixaFor is being developed as a diagnostic tool for primary aldosteronism, a cause of hypertension.
Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
| Country | Germany |
| Founded | 2019 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 75 |
| CEO | Dirk Pleimes |
Contact Details
Address: Robert-Rössle-Straße 10 Berlin, 13125 Germany | |
| Phone | 49 30 9489 2600 |
| Website | pentixapharm.com |
Stock Details
| Ticker Symbol | PTP |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dirk Pleimes | Chief Executive Officer |
| Jenny Schewe | Chief Financial Officer |